Endogenous nitric oxide modifies antigen-induced microvascular leakage in sensitized guinea pig airways. 1996

M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

To examine the role of endogenous nitric oxide in allergic airway inflammation, we investigated the effect of a nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester (l-NAME), on antigen-induced airway microvascular leakage in actively sensitized guinea pigs by using Evans blue dye. Three weeks after sensitization with ovalbumin (10 micrograms), the tracheas were cannulated, and lungs were artificially ventilated. Animals were pretreated with atropine and propranolol (both 1 mg/kg, intravenously) to avoid neural modification. Ovalbumin inhalation (3 mg/ml, 1 minute) challenge caused significant microvascular leakage in all airways portions, which was significantly suppressed in a dose-dependent manner by pretreatment with intravenous injection of L-NAME (1 and 10 mg/kg) but not with the inactive enantiomer D-NAME (10 mg/kg). This inhibition by L-NAME was significantly reversed by co-administration of L-arginine (100 mg/kg, intravenously). Pretreatment with a vasoconstrictor, phenylephrine (20 micrograms/kg, intravenously), had no inhibitory effects on antigen-induced airway microvascular leakage despite increasing systemic blood pressure. Inhalation of representative mast cell-derived mediators, histamine (2 mg/ml, 1 minute) or leukotriene D4 (5 micrograms/ml, 1 minute), produced significant microvascular leakage in all airways. L-NAME (10 mg/kg, intravenously) partially but significantly inhibited leukotriene D4-induced leakage, whereas histamine-induced leakage was not affected. These results suggest that endogenous nitric oxide acts to increase airway microvascular leakage after airway allergic reaction.

UI MeSH Term Description Entries
D007442 Intubation, Intratracheal A procedure involving placement of a tube into the trachea through the mouth or nose in order to provide a patient with oxygen and anesthesia. Intubation, Endotracheal,Endotracheal Intubation,Endotracheal Intubations,Intratracheal Intubation,Intratracheal Intubations,Intubations, Endotracheal,Intubations, Intratracheal
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D002199 Capillary Permeability The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement. Microvascular Permeability,Permeability, Capillary,Permeability, Microvascular,Vascular Permeability,Capillary Permeabilities,Microvascular Permeabilities,Permeabilities, Capillary,Permeabilities, Microvascular,Permeabilities, Vascular,Permeability, Vascular,Vascular Permeabilities
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate

Related Publications

M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
January 2001, The Annals of otology, rhinology, and laryngology,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
June 1991, European journal of pharmacology,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
February 1989, The American review of respiratory disease,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
December 2001, European journal of pharmacology,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
October 1992, European journal of pharmacology,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
January 1997, Life sciences,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
April 1992, European journal of pharmacology,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
January 2001, British journal of pharmacology,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
May 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
M Miura, and M Ichinose, and N Kageyama, and M Tomaki, and T Takahashi, and J Ishikawa, and Y Ohuchi, and T Oyake, and N Endoh, and K Shirato
September 1999, Immunopharmacology,
Copied contents to your clipboard!